Oruka Therapeutics (ORKA) Stock Price, News & Analysis

Company Overview

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Key Stats

• Today's Range: $25.16 to $26.33
• 50-Day Range: N/A
• 52-Week Range: $18.72 to $53.88
• Volume: 13,673 shs
• Average Volume: 49,698 shs
• Market Capitalization: $31.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.25
• Consensus Rating: Buy

ORKA Stock Analysis - Frequently Asked Questions

How have ORKA shares performed this year?

Oruka Therapeutics' stock was trading at $27.99 at the beginning of 2024. Since then, ORKA stock has decreased by 7.2% and is now trading at $25.97.
View the best growth stocks for 2024 here.

When did Oruka Therapeutics' stock split?

Shares of Oruka Therapeutics split before market open on Saturday, January 1st 2000. The 12-1 split was announced on Saturday, January 1st 2000. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, September 3rd 2024. An investor that had 100 shares of stock prior to the split would have 1,200 shares after the split.

How do I buy shares of Oruka Therapeutics?

Shares of ORKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 9/19/2024
• Next Earnings (Estimated): 10/16/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ORKA
• CUSIP: N/A
• CIK: 907654
• Web: www.arcabio.com
• Phone: 720-940-2100
• Fax: 720-208-9261
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $41.25
• High Stock Price Target: $44.00
• Low Stock Price Target: $40.00
• Potential Upside/Downside: +57.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,340,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.18%
• Return on Assets: -19.51%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.61
• Quick Ratio: 26.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $34.72 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 1,210,000
• Free Float: N/A
• Market Cap: $31.80 million
• Optionable: N/A
• Beta: 0.89